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Background. Inhaled antibiotics are commonly used in the treatment of cystic ﬁbrosis lung disease. A previous study suggested
neutrophil elastase activation by colistin in vitro. Here, we investigated direct eﬀects of the commonly used antibiotics colistin and
tobramycin on neutrophil elastase activity. Methods. Neutrophil elastase was measured spectrophotometrically. The antibiotics
colistin and tobramycin were added in diﬀerent concentrations with or without the addition of albumin. Results. Generally,
neutrophilelastaseactivitywaslowerintheabsenceofalbumincomparedtoitspresence.Bothantibiotics,colistinandtobramycin,
had inhibitory eﬀects on neutrophil elastase activity except for high concentrations of colistin when albumin was absent.
Conclusions. Our results suggest inhibitory eﬀects of colistin and tobramycin in vitro. There was a clear dependency of neutrophil
elastase measurements on the presence of albumin. Clinical studies are needed to investigate potential direct eﬀects of inhaled
antibiotics on neutrophil elastase activity in cystic ﬁbrosis airways.
1.Background
Cystic ﬁbrosis is the most common recessive disease in
Caucasians with a prevalence of about 1:2500 [1]. Cystic
ﬁbrosis is characterized by progressive lung destruction due
to chronic neutrophilic airway inﬂammation and bacterial
infection [2]. Most of the morbidity and mortality of cystic
ﬁbrosis patients results from the lung disease [3]. Large
amounts of neutrophils are targeted into the airways, mostly
by the chemokine interleukin 8, where they are primed,
activated and engage bacterial phagocytosis releasing high
amounts of oxidants and proteases [4]. Neutrophils derived
from cystic ﬁbrosis patients release signiﬁcantly higher
levels of neutrophil elastase when activated by interleukin 8
compared to healthy subjects or bronchiectatic patients [5].
It was suggested that neutrophils in cystic ﬁbrosis airway
environment undergo necrosis, rather than apoptosis [6, 7].
This leads to uncontrolled secretion of interleukin 8 with
further chemotaxis and accumulation of neutrophils and
an overwhelming release of neutrophil elastase. Collateral
damage of airway surface epithelium and destruction of
neighboring structures allow bacterial persistence in niches
and further perpetuation of inﬂammation [8, 9]. With ongo-
ing cystic ﬁbrosis lung disease, a state termed as prolonged
endobronchial protease activity (PEPA) is established [10].
We recently found that phagocytic activity is reduced in
cystic ﬁbrosis neutrophils supposedly due to proteolytic
cleavage of the speciﬁc interleukin 8 receptor CXCR1 which
plays a pivotal role in neutrophil phagocytosis of bacteria
most likely by neutrophil elastase [11].
Since the introduction of antibiotics in the mid 1950s
and the development of new antibiotic regimens, the mean
survival in cystic ﬁbrosis patients dramatically increased
[12].Afterintravenousorinhaledantibiotictherapybacterial
burden is reduced in the airways of cystic ﬁbrosis patients,
as is neutrophil burden, free elastase, and associated inﬂam-
matoryresponse [13–16].Inhaledtreatmentofcysticﬁbrosis
lung disease commonly includes nebulized antibiotics such
ascolistinandtobramycin[17].Inadditiontoindirectmech-
anisms of the antibiotics to reduce host inﬂammation by the
killing of bacteria and reduced concomitant inﬂammation,
direct actions of the antibiotics on the proteolytic milieu
are possible. Indeed, a previous study suggested neutrophil
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Figure 1: Eﬀects of colistin (a) and tobramycin (b) on neutrophil elastase measurement (absorption) are given for diﬀerent concentrations
of colistin and tobramycin (1, 10, 100, 1000μM) either in presence (ﬁlled symbols, continuous lines) or in absence (blank symbols, dashed
lines) of albumin. Data are presented as means of n = 3. ∗P < .05; ∗∗P < .01 compared to controls.
vitro[18]. The purpose of this study was to compare directly,
side by side, the eﬀects of colistin and tobramycin on
neutrophil elastase activity.
2. Methods
2.1. Neutrophil Elastase Spectrophotometric Assay. Neu-
trophil elastase activity was measured with the spe-
ciﬁc peptide substrate methoxysuccinyl-ala-ala-pro-val-p-
nitroanilide (MSAAPV-pNA—Sigma-Aldrich, Munich, Ger-
many) as previously described by Hilliard et al. [19]. Puriﬁed
human neutrophil elastase (Elastin Products Company,
Owensville, MO, USA) was diluted to ﬁnal concentrations of
0.5, 1, 2, 4, and 8μg/mL in an assay buﬀer (Dulbecco’s phos-
phate buﬀered saline, PAA Laboratories, Pasching, Austria)
in the presence or absence of albumin (0.1% bovine serum
albumin, Fermentas, St. Leon-Rot, Germany) to test whether
the presence of additional protein has an eﬀecton neutrophil
elastasemeasurements.Toinvestigateeﬀectsofantibioticson
neutrophil elastase measurements, colistin (colistimethate
sodium salt, Colistin CF, Gruenenthal, Aachen, Germany)
and tobramycin (Tobi, Novartis, Nuernberg, Germany) at
concentrations of 1, 10, 100 and 1000 μmol/L were added
to neutrophil elastase for 10 min (20
◦C) prior to analysis.
As a control for colistin we used the vehicle buﬀer provided
by the manufacturer to dissolve the antibiotics. As a control
for tobramycin we dissolved 11.25mg of sodium chloride
in 5mL aqua ad iniectabilia and adjusted the pH to 6.0
according to the product sheet of the manufacturer. Directly
after addition of the substrate, 96-well plates (Greiner Bio-
One, Frickenhausen, Germany) were measured at 405nm
absorbance on a plate reader (Anthos, Krefeld, Germany).
Samples were measured in duplicates and a standard curve
(range 0.5–8μg/mL) was included within the assay.
The used substrate is highly sensitive and speciﬁc to
neutrophil elastase [20, 21], and change of optical density
(OD) is directly proportional to the rate of p-nitroanilide
cleavage; thus change of OD indicates a change in speciﬁc
activity [19]. Neutrophil elastase activity was calculated
from the slope of the over-time increase in color formation
(change of OD) at a wavelength of 405nm. The slopes were
calculated by linear regression analysis of each experiment.
2.2. Eﬀect of Antibiotics and Albumin on Neutrophil Elastase
Activity. To test eﬀects of antibiotics on neutrophil elastase
measurements, colistin and tobramycin were added in
diﬀerent concentrations (ﬁnal concentration of 1, 10, 100,
1000μM) to neutrophil elastase in presence or absence
of albumin. Following a preincubation of 10 minutes the
substrate MSAAPV-pNA was added directly before mea-
surements and results were compared to samples without
antibiotics or albumin. The minimal inhibitory concentra-
tion for tobramycin is 8μg/mL [16], whereas the antibiotic
breakpoint for colistin is 2μg/ml [22]. Since inhaled antibi-
otics are known to reach high levels in airways, we used
concentration ranges from 1 to 1000μM for tobramycin and
colistin, which is equal to 0.47 to 467μg/mL and 1.16 to
1155μg/mL, respectively.
2.3. Statistics. Data are presented as mean or mean +/−
standard error of mean for the number of independentMediators of Inﬂammation 3
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Figure 2: Eﬀect of colistin (a) and (c) and tobramycin (b) and (d) in diﬀerent concentrations (1, 10, 100, 1000μM) on neutrophil elastase
activity measurements (neutrophil elastase concentration = 8μg/mL) in presence (ﬁlled symbols and contineous lines or ﬁlled columns) or
absence (blank symbols and dashed lines or empty columns) of albumin. In Figures 2(a) and 2(b) change of optical density (OD) over time
is given (mean of n = 3), in Figures 2(c) and 2(d) mean values for slopes of changes in OD over 10 minutes are expressed as means and SEM
(bars) and % changes compared to respective control are given of n = 3. ∗P < .05; ∗∗P < .01; ∗∗∗P < .001 compared to controls.
experiments indicated. The nonparametric Wilcoxon signed
rank test was performed for comparison of neutrophil elas-
tase measurements in the presence of albumin compared to
that in the absence of albumin. Repeated-measures analysis
of variance with Bonferroni post-hoc test was conducted to
analyze the eﬀect of diﬀerent concentrations of antibiotics
on neutrophil elastase measurements in the presence or
absence of albumin. Diﬀerences were considered statistically
signiﬁcant if P values were P < .05.
3. Results
P-nitroanilide cleavage by neutrophil elastase was concen-
tration-dependent over the range of neutrophil elastase4 Mediators of Inﬂammation
investigated (Figure 1) and was linear for various time
p e r i o d su pt o3 0m i n u t e s( n o ts h o w n ) .
To test the eﬀects of inhaled antibiotics used in the
treatment of cystic ﬁbrosis patients on neutrophil elastase
measurements in vitro, we added colistin and tobramycin
to the assay. The addition of either colistin or tobramycin
led to reduced substrate cleavage. This was signiﬁcant for
1μMa n d1 0 μMo fc o l i s t i n( P < .01 and P < .05, resp.)
and for 1μMa n d1 0μMo ft o b r a m y c i n( P < .01). At very
high concentrations no or only very small eﬀects were noted
(Figure 1).
To assess if the presence of proteins could aﬀect neut-
rophil elastase measurements, we added bovine serum albu-
min. p-nitroanalide cleavage was generally higher in the
presence of albumin than in its absence (P < .0001). In
order to assess neutrophil elastase activity, the change of
optical density over time was calculated from the slope of the
time curves (Figure 2) and the slopes were compared to each
other.
Lastly, we investigated the eﬀects of the antibiotics either
in presence or absence of albumin. In the presence of
albumin, colistin signiﬁcantly inhibited neutrophil elastase
activity by 16% to 24% (P < .01 for 1μM and 100μM; P
< .001 for 10μM; P < .05 for 1000μM) and tobramycin
by 23% to 37% (P < .05 for 1μM, 100μM and 1000μM; P
< .01 for 10μM) compared to controls without antibiotics.
Without albumin, colistin signiﬁcantly inhibited neutrophil
elastase by 73% to 79% at 1μMa n d1 0μM( P < .01) and
tobramycin by 74 to 82% (P < .05) (Figure 2).
Similar eﬀects were observed for the other neutrophil
elastase concentrations (data not shown).
4. Discussion
Colistin and tobramycin are widely used nebulized antibi-
otics in cystic ﬁbrosis patients and their eﬃcacy in treatment
of P. aeruginosa and the clinical amelioration of cystic
ﬁbrosis patients was shown in many studies [14–17, 23–25].
Surprisingly, a previous study suggested an activating eﬀect
of colistin on neutrophil elastase activity in vitro [18].
Therefore, we investigated direct eﬀects of the antibiotics
colistin and tobramycin used in patients with cystic ﬁbrosis
for inhalation on the measurements of neutrophil elastase
activity. Neutrophil elastase activity was inhibited by both
antibiotics except for high colistin concentrations. There was
no signiﬁcant enhancing eﬀect of these antibiotics, both in
the presence and absence of albumin. However, neutrophil
elastase activity was also dependent on albumin and was
signiﬁcantly elevated in its presence.
These in vitro data suggest that both colistin and
tobramycin may be slightly inhibitory on neutrophil elastase
activity. This result is in contrast to the previous study by
Jones et al. [18] in which the eﬀe c to fc o l i s t i no nn e u t r o p h i l
elastase activity in cystic ﬁbrosis sputum samples at increas-
ing colistin concentrations (3.9–500μM) was studied and
neutrophil elastase activity was already increased at lowest
colistin levels (3.9μM) compared to control incubations
without the addition of colistin.
Reasons for these diﬀerent results may include diﬀerent
colistin preparations and assay conditions used. As colistin
represents mainly polymyxin E, however, more than 30
minor components have been isolated [26] and its behavior
is critically dependent on its source and preparation which
were not indicated in the previous study. The presence
of protein signiﬁcantly aﬀects activity; however this does
not change the direction of the modulatory eﬀect of the
antibiotics, whereas its magnitude was inﬂuenced.
On the other hand, our results might lead to the assump-
tion that albumin itself had activating eﬀects on neutrophil
elastase and reduced inhibitory eﬀects of the antibiotics on
neutrophil elastase. This seems to be unlikely, because there
wasnodose-dependentchangeofneutrophilelastaseactivity
by the antibiotics. If protein-protein interactions between
albuminandtheantibioticsaﬀectthepharmacokineticactiv-
ityofneutrophilelastase,higherconcentrationsofantibiotics
would have had an inﬂuence on the measurements. Instead,
we suppose that the strong dependency of neutrophil
elastase activity on albumin was due to variable binding of
neutrophil elastase or substrate to tube surfaces, modulating
the availability of these components to neutrophil elastase.
The assay in the study of Jones et al. [18]w a sp e r f o r m e d
without addition of proteins like albumin. But the presence
of proteins in the assay may more likely represent the real
situation in cystic ﬁbrosis airways where high concentrations
of protein are present [27], aﬀecting neutrophil elastase
activity and therefore the experimental set-up with the
presence of protein may more likely represent the conditions
in cystic ﬁbrosis airways. Whereas our results suggest that
both tobramycin and colistin, have no activating eﬀect on
neutrophil elastase, it is obvious that one cannot predict
in vivo eﬀects from these data. Therefore, clinical studies
must assess potential direct eﬀects of inhaled antibiotics on
neutrophil elastase activity in cystic ﬁbrosis airways.
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